EDTA
Administration
- Type: Antidote (chelator)
- Dosage Forms:
- Routes of Administration: IV/IM
- Alternate names: Calcium Disodium Edathamil, Calcium Disodium Edetate, ethylenediamine tetraacetic acid, Edetic acid, Edetate calcium
Adult Dosing
- Asymptomatic or symptomatic lead poisoning, level 20-70 mcg/dL: 1000 mg/m(2)/day IV over 8-12h OR IM in divided doses q8-12 hours
- Administer with dimercaprol if level >70 mcg/dL or symptomatic
Pediatric Dosing
- Same as above
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: reduce dose if mild impairment, contraindicated if anuria or active renal disease
- Hepatic dosing: contraindicated in active hepatitis
Contraindications
- Allergy to class/drug
- Anuria, active renal disease
- Active hepatitis
Adverse Reactions
Serious
All listed here are relatively frequent complications
- Hypotension
- Thrombophlebitis
- Fever
- Nephrotoxicity
- Hypersensitivity reaction
Common
- Injection site pain
- Nausea/vomiting
- Myalgia
- Headache
Pharmacology
- Half-life: 20-60min
- Metabolism: Not metabolized
- Excretion: Renal
Mechanism of Action
- Divalent/trivalent metals (especially lead) replace calcium in EDTA forming stable, soluble complexes that are readily excreted